Krazati

Adagrasib, the active ingredient in Krazati, is a KRAS G12C inhibitor presented as a tablet for oral use. It targets KRAS G12C mutated non‑small cell lung cancer in adult patients who have this specific genetic alteration.

GNH USA supplies Krazati as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Krazati is a targeted therapy that acts on the KRAS G12C mutation pathway in lung cancer.

- KRAS G12C mutated non‑small cell lung cancer: provides a specific inhibitor for patients whose tumors carry the KRAS G12C alteration, aiming to improve disease control.

Adagrasib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of sickness often leading to vomiting. - Fatigue: persistent tiredness affecting daily activities. - Decreased appetite: reduced desire to eat. - Anemia: lowered red blood cell count causing weakness.

Serious or Rare Side Effects: - Elevated liver enzymes: potential liver injury requiring monitoring. - Interstitial lung disease: inflammation of lung tissue that can be life‑threatening. - Cardiac toxicity: arrhythmias or reduced heart function that need immediate medical attention.

Before initiating therapy with Krazati, several safety considerations should be observed. - Liver function monitoring: assess baseline enzymes and repeat regularly. - Cardiac assessment: evaluate ECG and cardiac history for potential toxicity. - Drug interaction review: check concomitant medications that affect CYP3A4. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with a specialist. - Baseline laboratory tests: complete blood count, renal function, and electrolytes. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Adagrasib can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase adagrasib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): require dose adjustment. - Acid‑reducing agents (e.g., proton pump inhibitors): may affect absorption. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): monitor for increased statin concentrations.